We are monitoring the impact of COVID-19 on APAC Monoclonal Antibody Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date September, 2021
ID: 12163
Share on
Share on

APAC Monoclonal Antibody Therapy Market Research Report – Segmented By Type, Application, Distribution channel, and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026.

Pulished: September, 2021
ID: 12163
Pages: 100

APAC Monoclonal Antibody Therapy Market Size (2021 to 2026)

The APAC monoclonal antibody therapy market was worth USD 37.72 billion in 2021 and is estimated to be growing at a CAGR of 18.34% to reach USD 87.56 billion by 2026.

Monoclonal antibodies (mAbs), a type of monospecific antibody (protective body inflammatory response), are made up of identical antibody molecules and are produced by a single cell clone or cell line.

Increased cancer prevalence, increased demand for cost-effective biosimilar monoclonal antibodies, high demand for biologics, and increased genomics R&D activities, as well as the introduction of technologically advanced genetic platforms, such as next-generation sequencing, are the major factors driving the growth of APAC monoclonal antibody therapy market. Cancer, autoimmune diseases, infectious diseases, inflammatory diseases, and microbial diseases are all on the rise, contributing to a surge in demand for monoclonal antibody therapy. Increased research collaborations for the development of a robust drug pipeline, increased awareness of the applications of monoclonal antibodies (mAb) therapy among patients and physicians, all contribute to the market's growth in Asia.

The APAC monoclonal antibody therapy market is expected to rise due to ongoing developments in monoclonal antibodies, the availability of advanced healthcare systems, and a large increase in demand for advanced healthcare facilities. The monoclonal antibody market is predicted to rise because of a surge in leading manufacturers' focus on increasing their geographical presence in rising Asia-Pacific countries to acquire a high market share. In the monoclonal antibody market, the prevalence of chronic and uncommon diseases is a key revenue growth driver. For example, patients with cancer require long-term medicine and frequent delivery of moAb as directed throughout therapy.

Along with disease prevalence, industry players' ongoing attempts to create new products will boost the APAC monoclonal antibody therapy market. The growing awareness of monoclonal antibody therapy's reduced side effects compared to medicines and chemotherapy for cancer treatment may boost the market growth. Monoclonal antibody therapy is a new and exciting treatment option for chronic disorders, including cancer. Preference for these treatments is gradually increasing, resulting in sales of a few products, such as Herceptin and Humira. Major research collaborations are developing as a crucial monoclonal antibody therapy market trend, due to pharmaceutical giants' increased focus on the discovery of novel monoclonal antibodies. New manufacturers seek to enter the highly competitive market as the use of these revolutionary pharmaceuticals grows, and effective cooperation can help them maintain their position.

However, The monoclonal antibody market is predicted to grow slowly due to low demand in this nation. The high cost of monoclonal antibody therapy makes them expensive for the low- and middle-income population, restricting market expansion.

This research report on the APAC monoclonal antibody therapy market has been segmented and sub-segmented into the following categories:

By Type:

  • Human mAb
  • Humanized mAb
  • Chimeric mAb
  • Murine mAb

By Application:

  • Cancer
  • Autoimmune Diseases

By Distribution Channel:

  • Hospital Pharmacy Retail Pharmacy
  • Online Pharmacy

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand, Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

APAC monoclonal antibody therapy market is growing due to an increase in the number of initiatives, increased government spending for overall R&D of monoclonal antibody therapy, and a rise in the number of product approvals. Several big manufacturers are focusing on R&D to expand the usage of established medications for new diseases. This has aided enterprises in increasing revenue from mAb products, hence contributing to overall market growth. As chronic diseases become more common in the Asia Pacific, factors such as the introduction of solutions to meet patient demands and the availability of health reimbursement policies for therapeutic monoclonal antibodies to treat these diseases can help to boost the regional market rise.

KEY MARKET PLAYERS:

Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., CASI Pharmaceuticals, Eli Lilly and Co., Merck & Co., Inc., Changchun Zhongyingfeng Science And Technology Co., Ltd, Hangzhou Immuno Biotech Co. Ltd, Nantong Egens Biotechnology Co. Ltd are some of the dominating companies in the APAC monoclonal antibody therapy market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences               

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape            

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 APAC Monoclonal Antibody Therapy Market - By Type:                       

                        6.1.1 Human mAb      

                        6.1.2 Humanized mAb

                        6.1.3 Chimeric mAb   

                        6.1.4 Murine mAb      

                        6.1.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.1.6 Y-o-Y Growth Rate Analysis      

                        6.1.7 Market Attractiveness Index    

            6.2 APAC Monoclonal Antibody Therapy Market -By Application:             

                        6.2.1 Cancer   

                        6.2.2 Autoimmune Diseases  

                        6.2.3 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.4 Y-o-Y Growth Rate Analysis      

                        6.2.5 Market Attractiveness Index    

            6.3 APAC Monoclonal Antibody Therapy Market -By Distribution Channel:                      

                        6.3.1 Hospital Pharmacy Retail Pharmacy    

                        6.3.2 Online Pharmacy          

                        6.3.3 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.4 Y-o-Y Growth Rate Analysis      

                        6.3.5 Market Attractiveness Index    

7. Geographical Landscape                            

            7.1 Asia Pacific                       

                        7.1.1 By Country        

                                    7.1.1.1 China

                                    7.1.1.2 India

                                    7.1.1.3 Japan

                                    7.1.1.4 South Korea

                                    7.1.1.5 South East Asia

                                    7.1.1.6 Australia & NZ

                                    7.1.1.7 Rest of Asia-Pacific

                        7.1.2 By Type 

                        7.1.3 By Application   

                        7.1.4 By Distribution Channel:           

8. Key Player Analysis                        

            8.1 Pfizer Inc.             

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Novartis AG                      

            8.3 Bayer AG              

            8.4 Sanofi S.A.            

            8.5 CASI Pharmaceuticals                  

            8.6 Eli Lilly and Co.                 

            8.7 Merck & Co., Inc.             

            8.8 Changchun Zhongyingfeng Science And Technology Co., Ltd                 

            8.9 Hangzhou Immuno Biotech Co. Ltd                     

            8.10 Nantong Egens Biotechnology Co. Ltd              

9. Market Outlook & Investment Opportunities                               

10.Appendix                           

            List of Tables              

            List of Figures 

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of type, application, distribution channel, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Asia Pacific Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )

  2. Asia Pacific Human mAb Market By Region, From 2021 to 2026 ( USD Billion )

  3. Asia Pacific Humanized mAb Market By Region, From 2021 to 2026 ( USD Billion )

  4. Asia Pacific Chimeric mAb Market By Region, From 2021 to 2026 ( USD Billion )

  5. Asia Pacific Murine mAb Market By Region, From 2021 to 2026 ( USD Billion )

  6. Asia Pacific Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )

  7. Asia Pacific Cancer Market By Region, From 2021 to 2026 ( USD Billion )

  8. Asia Pacific Autoimmune Diseases Market By Region, From 2021 to 2026 ( USD Billion )

  9. Asia Pacific Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  10. Asia Pacific Hospital Pharmacy Retail Pharmacy Market By Region, From 2021 to 2026 ( USD Billion )

  11. Asia Pacific Online Pharmacy Market By Region, From 2021 to 2026 ( USD Billion )

  12. Japan Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )

  13. Japan Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )

  14. Japan Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  15. China Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )

  16. China Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )

  17. China Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  18. India Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )

  19. India Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )

  20. India Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  21. Australia Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )

  22. Australia Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )

  23. Australia Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  24. South Korea Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )

  25. South Korea Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )

  26. South Korea Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample